# Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas

> **NCT01478321** · PHASE2 · TERMINATED · sponsor: **Northwestern University** · enrollment: 54 (actual)

## Conditions studied

- Adult Anaplastic Astrocytoma
- Adult Anaplastic Ependymoma
- Adult Anaplastic Oligodendroglioma
- Adult Giant Cell Glioblastoma
- Adult Glioblastoma

## Interventions

- **DRUG:** Temozolomide
- **RADIATION:** hypofractionated radiation therapy
- **BIOLOGICAL:** bevacizumab
- **OTHER:** questionnaire administration

## Key facts

- **NCT ID:** NCT01478321
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-12-14
- **Primary completion:** 2018-09-12
- **Final completion:** 2018-09-12
- **Target enrollment:** 54 (ACTUAL)
- **Why stopped:** Slow accrual to some cohorts
- **Last updated:** 2020-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01478321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01478321, "Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01478321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*